MarketPulse

cancer therapy

17 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Crashes 21% Following FDA Warning on Cancer Therapy

ImmunityBio faces securities fraud lawsuit after FDA warning letter on Anktiva cancer therapy. Stock plummeted to $7.42. Class action period open through May 26.
IBRXsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

Pfizer's ELREXFIO Demonstrates Superior Efficacy in Late-Stage Myeloma Trial

Pfizer's ELREXFIO cancer therapy shows superior efficacy in Phase 3 myeloma trial, but stock declines amid analyst skepticism about growth prospects.
PFEPhase 3 trialclinical trial results
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Plummets 21% After FDA Warning on Cancer Drug Claims

ImmunityBio faces securities fraud lawsuit following FDA warning letter about misleading Anktiva advertisements. Stock dropped to $7.42 per share.
IBRXsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

Big Pharma Circles Inhibrx Cancer Assets in $9B Spin-Off Deal

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.
JNJMRKPFELLYSNY+2biotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Faces Securities Fraud Class Action After FDA Warning, Stock Crashes 21%

ImmunityBio faces securities fraud lawsuit after FDA warns of false cancer cure claims for Anktiva, stock crashes 21% to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Ascentage Pharma Group International

Ascentage Pharma Showcases Pipeline at ASCO 2026 With Three Oral Presentations

Ascentage Pharma selected for six abstracts at ASCO 2026, including three rapid oral presentations featuring data on three key oncology drug candidates.
AAPGclinical trialsoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Bispecific Antibodies Poised for $60B Market by 2031 as 550+ Trials Reshape Therapeutics

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.
AMGNJNJPFEABBVRHHBY+3clinical trialsautoimmune diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Plunges 21% After FDA Warning on Cancer Drug Claims

ImmunityBio faces securities fraud lawsuit following FDA warning letter about misleading Anktiva advertisements. Stock fell to $7.42; investors have until May 26 to file claims.
IBRXsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

Revolution Medicines Soars 40% on Pancreatic Cancer Breakthrough, Despite Merck Deal Collapse

Revolution Medicines surges 40% after Phase 3 trial shows daraxonrasib doubles survival in metastatic pancreatic cancer versus chemotherapy.
MRKRVMDRVMDWPhase 3 trialclinical trial results
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Unveils Novel Cancer Therapy Data Ahead of AACR 2026 Meeting

HUTCHMED to present preclinical data on first-in-class PI3K/PIKK therapy and updated Phase Ib/II surufatinib combination trial results at AACR Annual Meeting 2026.
HCMoncologycancer therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Faces Securities Fraud Suit After FDA Warning Triggers 21% Stock Plunge

ImmunityBio hit with securities fraud class action following FDA warning letter over misleading Anktiva cancer therapy ads. Stock fell 21% to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Crashes 21% After FDA Warning on Cancer Drug Marketing

ImmunityBio faces securities fraud lawsuit following FDA warning letter about Anktiva cancer therapy misleading ads. Stock plummeted to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Ascentage Pharma Group International

Ascentage Pharma's Revenue Surges 90% on Olverembatinib, Lisaftoclax Growth

Ascentage Pharma reports 90% revenue growth to $82.1M in 2025, driven by Olverembatinib and newly launched Lisaftoclax, despite $177.7M net loss.
AAPGbiopharmaceuticalcancer therapy
BenzingaBenzinga··Lekha Gupta

NASA Awards Redwire $4M for Drug Development, Bolstering Space-Based Research Platform

NASA awards Redwire $4 million for drug development in cancer, osteoporosis, and obesity. Shares rise 0.98% following funding announcement.
RDWspace technologypharmaceutical innovation
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Actuate Therapeutics to Unveil Cancer Pipeline Expansion at Citizens Conference

Actuate Therapeutics plans to present at the Citizens Life Sciences Conference on March 10, advancing elraglusib tablet into Phase 1/2 oncology trials launching H2 2026.
ACTUcancer therapypipeline expansion
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Oncology-Focused Arcellx in $7.8B Cash Deal

Gilead acquires oncology firm Arcellx for $7.8 billion in cash, adding CAR T-cell cancer therapy to its pipeline. Deal expected to close Q4 2024.
GILDACLXacquisitionM&A
The Motley FoolThe Motley Fool··Jonathan Ponciano

Redmile Group Doubles Down on Nurix With $63M Investment Despite Underperformance

Redmile Group adds $63M to Nurix stake despite stock decline, betting on promising BTK degrader clinical data and upcoming registrational trials.
NRIXKRYSstock underperformanceclinical trial